Skip to content
TriangleGet started
← Indolent B-Cell Non-Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for Indolent, Noncontiguous Stage II/III/IV B-Cell NHL

Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Indolent, Noncontiguous Stage II/III/IV B-Cell Non-Hodgkin Lymphoma

Treatment options for indolent, noncontiguous stage II/III/IV B-cell NHL include:

Watchful waiting for asymptomatic patients.

Source links and citations

Rituximab alone or in combination with cytotoxic agents used in front-line therapy.

Source links and citations

Lenalidomide and rituximab.

Source links and citations

Maintenance rituximab.

Source links and citations

Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy.

Source links and citations

Because none of the therapies listed above are curative for advanced-stage disease, innovative approaches are under clinical evaluation.

Continue within this section

Watchful waiting for asymptomatic patients →Rituximab alone or in combination with cytotoxic agents used in front-line therapy →Lenalidomide and rituximab →Maintenance rituximab →Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy →

Preserved source evidence · Independent clinical review pending · Not medical advice